NeoMark

ICT Enabled Prediction of Cancer Reoccurrence

Coordinatore	AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA    more  Organization address address: VIA GRAMSCI 14 city: PARMA postcode: 43100 contact info Titolo: Mr. Nome: Michele Cognome: MALANCA Email: send email Telefono: 390522000000 Fax: 390522000000
Nazionalità Coordinatore	Italy [IT]
Totale costo	3˙981˙536 €
EC contributo	2˙896˙600 €
Programma	FP7-ICT Specific Programme "Cooperation": Information and communication technologies
Code Call	FP7-ICT-2007-2
Funding Scheme	CP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-06-01   -   2011-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA  Organization address address: VIA GRAMSCI 14 city: PARMA postcode: 43100 contact info Titolo: Mr. Nome: Michele Cognome: MALANCA Email: send email Telefono: 390522000000 Fax: 390522000000	IT (PARMA)	coordinator	0.00
2	FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V  Organization address address: Hansastrasse city: MUENCHEN postcode: 80686 contact info Titolo: Mr. Nome: Christoph Cognome: Schulte Email: send email Telefono: +49 89 1205 2728 Fax: +49 89 1205 7534	DE (MUENCHEN)	participant	0.00
3	FUNDACION MD ANDERSON INTERNATIONAL ESPANA  Organization address address: CALLE GOMEZ HEMANS 2 city: MADRID postcode: 28033 contact info Titolo: Ms. Nome: ISABEL Cognome: CRESPO Email: send email Telefono: 34917878625 Fax: 34917878641	ES (MADRID)	participant	0.00
4	ISTITUTI FISIOTERAPICI OSPITALIERI  Organization address address: VIA CHIANESI city: ROMA postcode: 144 contact info Titolo: Mr. Nome: ENRICO Cognome: DEL BAGLIVO Email: send email Telefono: 390653000000 Fax: 390653000000	IT (ROMA)	participant	0.00
5	LINK CONSULTING - TECNOLOGIAS DE INFORMACAO S.A.  Organization address address: AVENIDA DUQUE D'AVILA 23 city: LISBOA postcode: 1000-138 contact info Titolo: Prof. Nome: Pedro Cognome: Sousa Email: send email Telefono: +351 213 100 12 Fax: +351 213 100 10	PT (LISBOA)	participant	0.00
6	MULTIMED S.R.L.  Organization address address: VIA PORTINARI DEL PO 21 city: CREMONA postcode: 26100 contact info Titolo: Dr. Nome: Diego Cognome: Ardigò Email: send email Telefono: 393294000000 Fax: +39 329 4218474	IT (CREMONA)	participant	0.00
7	PANEPISTIMIO IOANNINON  Organization address address: LEOFOROS STAVROS S NIARCHOS, PANEPISTIMIOUPOLI IOANNINON city: IOANNINA postcode: 45110 contact info Titolo: Mr. Nome: GEORGIOS Cognome: DETSIKAS Email: send email Telefono: 302651000000 Fax: 302651000000	EL (IOANNINA)	participant	0.00
8	STMICROELECTRONICS SRL  Organization address address: VIA C.OLIVETTI city: AGRATE BRIANZA postcode: 20041 contact info Titolo: Dr. Nome: MARIA GRAZIA Cognome: PODESTA' Email: send email Telefono: 390396000000 Fax: 390396000000	IT (AGRATE BRIANZA)	participant	0.00
9	UNIVERSIDAD POLITECNICA DE MADRID  Organization address address: Calle Ramiro de Maeztu city: MADRID postcode: 28040 contact info Titolo: Prof. Nome: GONZALO Cognome: LEON Email: send email Telefono: +34 913366048 Fax: 34913365974	ES (MADRID)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

NeoMark will perform research in the integration of heterogeneous clinical, laboratory, molecular and imaging data to develop a data integration environment facilitating multiscale and multilevel modeling, aimed at advancing models and methods currently in use to predict neoplastic reoccurrences, and to apply it to the study of oral cancer.nSpecifically the scientific target will be to apply this multi-level data integration environment to the monitoring of the disease after remission, in order to early identify local or metastatic reoccurrence of the disease.nThe technical target will be the development of two functional envirnments: one for the definition of biomarker profiles and one for the follow-up of the evolution of the disease. They will be based on the 'fusion' of information from clinical data from health records and standard laboratory markers; from histological data from tumor mass specimens; from high-throughput genomic data from tumor tissue specimens, profiling gene expression at whole-genome level by oligo-RNA microarrays; from high-throughput genomic data from circulating cells specimens (whole blood sample), profiling gene expression at whole-genome level by oligo-RNA microarrays; from imaging data of the prime tumor mass (and secondary localizations if present) through imaging techniques, including image fusion, where relevant.nThe outcomes of the project will be validated in two primary Clinical Centres in Spain and in Italy.nIn this phase the early exploitation of NeoMark will also be assessed through the use of a RT-PCR platform to develop highly individual diagnostic tests to be used both at the time of first diagnosis, as well as for reoccurrence identification.